2020 Year in Review – Securities Litigation Against Life Sciences and Healthcare Companies

Over the past several years, there has been a substantial increase in the number of securities class actions filed against publicly traded life sciences, pharmaceutical, medical device, biotech, and health care product and service companies. That trend has continued in 2020 despite—and in some cases because of—COVID-19.

In this webinar, we will discuss the data and trends for securities litigation case filings, decisions, and settlements, and some of the more significant and interesting decisions of 2020 in the First, Second and Ninth Circuit Courts of Appeals and their respective district courts. We will provide in-depth analysis of the potential implications of these decisions, and discuss practical steps you can take to make informed choices related to your business, including your public disclosures.